149 related articles for article (PubMed ID: 18160963)
1. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients.
Kong NC; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; Calbo-Torrecillas F; López de Novales E; Srinivasa K; Stoffel M; Hoet B
Kidney Int; 2008 Apr; 73(7):856-62. PubMed ID: 18160963
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
Tong NK; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; de Juanes JR; Arrazola P; Calbo-Torrecillas F; de Novales EL; Hamtiaux V; Lievens M; Stoffel M
Kidney Int; 2005 Nov; 68(5):2298-303. PubMed ID: 16221232
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study.
Fabrizi F; Tarantino A; Castelnovo C; Martin P; Messa P
Kidney Blood Press Res; 2015; 40(6):584-92. PubMed ID: 26566033
[TBL] [Abstract][Full Text] [Related]
4. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency.
Surquin M; Tielemans C; Nortier J; Jadoul M; Peeters P; Ryba M; Roznovsky L; Domán J; Barthelemy X; Crasta PD; Messier M; Houard S
Hum Vaccin; 2011 Sep; 7(9):913-8. PubMed ID: 21892006
[TBL] [Abstract][Full Text] [Related]
5. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine.
Surquin M; Tielemans CL; Kulcsár I; Ryba M; Vörös P; Mat O; Treille S; Dhaene M; Stolear JC; Kuriyakose SO; Leyssen MX; Houard SA
Kidney Int; 2010 Feb; 77(3):247-55. PubMed ID: 19940840
[TBL] [Abstract][Full Text] [Related]
6. Transiently positive hepatitis B surface antigen after vaccination with the new hepatitis B vaccine HBV-AS04.
Vanacker A; Vandewiele I; Verbanck J; Schepkens H; De Schoenmakere G; De Laere E; Maes B
Am J Kidney Dis; 2008 Nov; 52(5):1028-9. PubMed ID: 18971027
[No Abstract] [Full Text] [Related]
7. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
[TBL] [Abstract][Full Text] [Related]
8. HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population.
Fabrizi F; Cerutti R; Nardelli L; Tripodi F; Messa P
Clin Res Hepatol Gastroenterol; 2020 Feb; 44(1):49-56. PubMed ID: 31327620
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
[TBL] [Abstract][Full Text] [Related]
10. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.
Avdicova M; Crasta PD; Hardt K; Kovac M
Vaccine; 2015 May; 33(23):2727-33. PubMed ID: 24962750
[TBL] [Abstract][Full Text] [Related]
11. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.
Girndt M; Plüer M; Dellanna F; Michelsen AK; Beige J; Toussaint K; Wehweck HJ; Koch M; Hafezi Rachti S; Faust J; Bosselmann HP; Witzke O; Janssen RS;
Hum Vaccin Immunother; 2022 Nov; 18(6):2136912. PubMed ID: 36269938
[TBL] [Abstract][Full Text] [Related]
14. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
[TBL] [Abstract][Full Text] [Related]
15. Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan.
Su FH; Bai CH; Chu FY; Lin YS; Su CT; Yeh CC
Vaccine; 2012 Jun; 30(27):4034-9. PubMed ID: 22531558
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C
Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
[TBL] [Abstract][Full Text] [Related]
19. Adjuvanted recombinant HBV vaccine (HBV-AS04) is effective over extended follow-up in dialysis population. An open-label non randomized trial.
Fabrizi F; Cerutti R; Garcia-Agudo R; Bellincioni C; Porata G; Frontini G; Aoufi-Rabih S; Messa P
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):905-912. PubMed ID: 32144074
[TBL] [Abstract][Full Text] [Related]
20. Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (booster effect).
Azarkeivan A; Karimi G; Shaiegan M; Maghsudlu M; Tabbaroki A
Pediatr Hematol Oncol; 2009 Jun; 26(4):195-201. PubMed ID: 19437322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
